Нуждаются ли пациенты с атеросклерозом периферических артерий в медикаментозной терапии до проведения реваскуляризации?
________________________________________________
Barbarash O.L., Kashtalap V.V. Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization? Therapeutic Archive. 2019; 91 (12): 129–134. DOI: 10.26442/00403660.2019.12.000498
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: периферический атеросклероз, ишемическая болезнь сердца, мультифокальный атеросклероз, прогноз, антитромботическая терапия, ривароксабан.
________________________________________________
In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.
Keywords: peripheral atherosclerosis, chronic coronary heart disease, multifocal atherosclerosis, prognosis, antithrombotic therapy, rivaroxaban.
2. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol. 1994;23:1091-5. doi: 10.1016/0735-1097(94)90596-7
3. Smolderen KG, Bell A, Lei Y, Cohen EA, Steg PG, Bhatt DL, Mahoney EM, on behalf of the REACH registry investigators. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol. 2010 Oct;26(8):e297-e305. doi: 10.1016/s0828-282x(10)70437-2
4. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al; REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006 Apr;151(4):786.e1-10. doi: 10.1016/j.ahj.2005.11.004
5. Manfrini O, Amaduzzi PL, Cenko E, Bugiardini R. Prognostic implications of peripheral artery disease in coronary artery disease. Curr Opin Pharmacol. 2018;39:121-8. doi: 10.1016/j.coph.2018.04.005
6. Барбараш О.Л., Кашталап В.В. Пациент с ишемической болезнью сердца и мультифокальным атеросклерозом. Как оптимизировать прогноз? Медицинский совет. 2018;16:32-8 [Barbarash OL, Kashtalap VV. A patient with coronary artery disease and multifocal atherosclerosis. How to optimize the prognosis? Medical Council. 2018;16:32-8 (In Russ.)]. doi: 10.21518/2079-701X-2018-16-32-38
7. Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Reid CM, et al; REACH Registry Investigators. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: insights from the REACH Registry. Clin Cardiol. 2017;40:710-8. doi: 10.1002/clc.22721
8. Безденежных А.В., Сумин А.Н., Иванов С.В., Барбараш О.Л. Предикторы госпитальных осложнений коронарного шунтирования: роль мультифокального атеросклероза. Сибирский медицинский журнал. 2016;31(1):35-41 [Bezdenezhnikh AV, Sumin AN, Ivanov SV, Barbarash OL. Predictors of hospital complications after coronary artery bypass grafting: the role of multifocal atherosclerosis. Siberian Medical Journal. 2016;31(1):35-41 (In Russ.)].
9. Гайфулин Р.А., Сумин А.Н., Иванов С.В., Барбараш Л.С. Выживаемость после хирургического лечения больных с мультифокальным атеросклерозом в различных возрастных группах. Комплексные проблемы сердечно-сосудистых заболеваний. 2017;6(2):6-18 [Gajfulin RA, Sumin AN, Ivanov SV, Barbarash LS. Survival after surgical treatment of multifocal atherosclerosis. Complex Issues of Cardiovascular Diseases. 2017;6(2):6-18 (In Russ.)].
10. Барбараш О.Л., Кашталап В.В. Атеросклероз периферических артерий и артериальная гипертония. Особенности антигипертензивной терапии. Медицинский алфавит. 2019;1(3):12-6 [Barbarash OL, Kashtalap VV. Atherosclerosis of peripheral arteries and arterial hypertension. Features of antihypertensive therapy. Medical Alphabet. 2019;1(3):12-6 (In Russ.)]. doi: 10.33667/2078-5631-2019-1-3(378)-12-16
11. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-821. doi: 10.1093/eurheartj/ehx095
12. Welten GM, Chonchol M, Schouten O, Hoeks S, Bax JJ, van Domburg RT, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant. 2008 Dec;23(12):3867-73. doi: 10.1093/ndt/gfn381
13. Kumbhani DJ, Steg PG, Cannon CP, et al. REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. doi: 10.1093/eurheartj/ehu080
14. Сумин А.Н., Косова М.А., Медведева Ю.Д., Щеглова А.В., Макаров С.А., Артамонова Г.В., Барбараш Л.С. Амбулаторное наблюдение больных атеросклерозом нижних конечностей с позиций кардиолога. Российский кардиологический журнал. 2016;21(12):58-63 [Sumin AN, Kosova MA, Medvedeva YuD, Shcheglova AV, Makarov SA, Artamonova GV, Barbarash LS. Outpatient follow-up of the extremites atherosclerosis patients from cardiologist point of view. Russian Journal of Cardiology. 2016;21(12):58-63 (In Russ.)]. doi: 10.15829/1560-4071-2016-12-58-63
15. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:1465-508. doi: 10.1016/j.jacc.2016.11.007
16. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61:2S-41S. doi: 10.1016/j.jvs.2014.12.006
17. Brass EP, Hiatt WR. Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. Circulation. 2018 Mar 20;137(12):1304. doi: 10.1161/CIRCULATIONAHA.117.032707
18. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, et al. Underestimated and underrecognized: the late consequences of acute coronary syndrome (GRACE UKBelgian Study). Eur Heart J. 2010;31:2755-64. doi: 10.1093/eurheartj/ehq326
19. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. REACH Registry Investigators Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-7. doi: 10.1001/jama.2010.1322
20. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70. doi: 10.1093/eurheartj/ehu505
21. Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung S-C, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2:172-83. doi: 10.1093/ehjqcco/qcw004
22. Барбараш О.Л., Кашталап В.В. Клопидогрел в составе двойной дезагрегантной терапии при ОКС: обоснованный выбор в сложных клинических ситуациях. Медицинский совет. 2019;(5):20-9 [Barbarash OL, Kashtalap VV. Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations. Medical Council. 2019;(5):20-9 (In Russ.)]. doi: 10.21518/2079-701X-2019-5-20-29/
23. Gurbel PA, Fox KAA, Tantry US, Ten Cate H, Weitz JI. Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation. 2019 Apr 30;139(18):2170-85. doi: 10.1161/CIRCULATIONAHA.118.033580
24. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. doi: 10.1056/NEJMoa0904327
25. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al; for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800. doi: 10.1056/NEJMoa1500857
26. Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, et al; for the EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376: 32-40. doi: 10.1056/NEJMoa1611688
27. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al; for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35-43. doi: 10.1056/NEJMc1610106
28. Кашталап В.В., Барбараш О.Л. Актуальные проблемы антитромботической терапии при остром коронарном синдроме (по материалам Европейского конгресса кардиологов 2017 г.). Медицинский совет. 2017;(12):82-8 [Kashtalap VV, Barbarash OL. Actual problems of antithrombotic therapy in acute coronary syndrome (following the material presented at the European society of cardiology congress 2017). Medical Council. 2017;(12):82-8 (In Russ.)]. doi: 10.21518/2079-701X-2017-12-82-88/
29. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8. doi: 10.1016/ j.jacc.2007.03.025
30. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504-14. PMID: 12871286
31. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al; for the APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708. doi: 10.1056/NEJMoa1105819
32. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol. 2017;33:1027-35. doi: 10.1016/j.cjca.2017.06.001
33. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al; for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. doi: 10.1056/NEJMoa1112277
34. Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30. doi: 10.1056/NEJMoa1709118
35. Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS TIMI 54. J Am Coll Cardiol. 2017;70:1368-75. doi: 10.1016/j.jacc.2017.07.768
36. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al; on behalf of the COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017. doi: 10.1016/S0140-6736(17)32458-3/
37. Значение результатов исследования COMPASS для клинической практики. Заключение совета экспертов от 22 ноября 2017 г. Атеротромбоз. 2018;(1):19-25 [The significance of COMPASS study results for clinical practice. Conclusion of the Board of Experts of November 22, 2017. Atherothrombosis. 2018;(1):19-25 (In Russ.)].
________________________________________________
1. [Barbarash OL, Kashtalap VV. Diagnosis of latent forms of non-coronary atherosclerosis in acute coronary syndrome patients. Is there any practical sense? Complex Issues of Cardiovascular Diseases. 2012;(1):12-6 (In Russ.)].
2. Eagle KA, Rihal CS, Foster ED, Mickel MC, Gersh BJ. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol. 1994;23:1091-5. doi: 10.1016/0735-1097(94)90596-7
3. Smolderen KG, Bell A, Lei Y, Cohen EA, Steg PG, Bhatt DL, Mahoney EM, on behalf of the REACH registry investigators. One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol. 2010 Oct;26(8):e297-e305. doi: 10.1016/s0828-282x(10)70437-2
4. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al; REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006 Apr;151(4):786.e1-10. doi: 10.1016/j.ahj.2005.11.004
5. Manfrini O, Amaduzzi PL, Cenko E, Bugiardini R. Prognostic implications of peripheral artery disease in coronary artery disease. Curr Opin Pharmacol. 2018;39:121-8. doi: 10.1016/j.coph.2018.04.005
6. [Barbarash OL, Kashtalap VV. A patient with coronary artery disease and multifocal atherosclerosis. How to optimize the prognosis? Medical Council. 2018;16:32-8 (In Russ.)]. doi: 10.21518/2079-701X-2018-16-32-38
7. Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Reid CM, et al; REACH Registry Investigators. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: insights from the REACH Registry. Clin Cardiol. 2017;40:710-8. doi: 10.1002/clc.22721
8. [Bezdenezhnikh AV, Sumin AN, Ivanov SV, Barbarash OL. Predictors of hospital complications after coronary artery bypass grafting: the role of multifocal atherosclerosis. Siberian Medical Journal. 2016;31(1):35-41 (In Russ.)].
9. [Gajfulin RA, Sumin AN, Ivanov SV, Barbarash LS. Survival after surgical treatment of multifocal atherosclerosis. Complex Issues of Cardiovascular Diseases. 2017;6(2):6-18 (In Russ.)].
10. [Barbarash OL, Kashtalap VV. Atherosclerosis of peripheral arteries and arterial hypertension. Features of antihypertensive therapy. Medical Alphabet. 2019;1(3):12-6 (In Russ.)]. doi: 10.33667/2078-5631-2019-1-3(378)-12-16
11. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-821. doi: 10.1093/eurheartj/ehx095
12. Welten GM, Chonchol M, Schouten O, Hoeks S, Bax JJ, van Domburg RT, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant. 2008 Dec;23(12):3867-73. doi: 10.1093/ndt/gfn381
13. Kumbhani DJ, Steg PG, Cannon CP, et al. REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. doi: 10.1093/eurheartj/ehu080
14. [Sumin AN, Kosova MA, Medvedeva YuD, Shcheglova AV, Makarov SA, Artamonova GV, Barbarash LS. Outpatient follow-up of the extremites atherosclerosis patients from cardiologist point of view. Russian Journal of Cardiology. 2016;21(12):58-63 (In Russ.)]. doi: 10.15829/1560-4071-2016-12-58-63
15. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:1465-508. doi: 10.1016/j.jacc.2016.11.007
16. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61:2S-41S. doi: 10.1016/j.jvs.2014.12.006
17. Brass EP, Hiatt WR. Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. Circulation. 2018 Mar 20;137(12):1304. doi: 10.1161/CIRCULATIONAHA.117.032707
18. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, et al. Underestimated and underrecognized: the late consequences of acute coronary syndrome (GRACE UKBelgian Study). Eur Heart J. 2010;31:2755-64. doi: 10.1093/eurheartj/ehq326
19. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. REACH Registry Investigators Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-7. doi: 10.1001/jama.2010.1322
20. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70. doi: 10.1093/eurheartj/ehu505
21. Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung S-C, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2:172-83. doi: 10.1093/ehjqcco/qcw004
22. [Barbarash OL, Kashtalap VV. Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations. Medical Council. 2019;(5):20-9 (In Russ.)]. doi: 10.21518/2079-701X-2019-5-20-29/
23. Gurbel PA, Fox KAA, Tantry US, Ten Cate H, Weitz JI. Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation. 2019 Apr 30;139(18):2170-85. doi: 10.1161/CIRCULATIONAHA.118.033580
24. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. doi: 10.1056/NEJMoa0904327
25. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al; for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800. doi: 10.1056/NEJMoa1500857
26. Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, et al; for the EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376: 32-40. doi: 10.1056/NEJMoa1611688
27. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al; for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35-43. doi: 10.1056/NEJMc1610106
28. К[Kashtalap VV, Barbarash OL. Actual problems of antithrombotic therapy in acute coronary syndrome (following the material presented at the European society of cardiology congress 2017). Medical Council. 2017;(12):82-8 (In Russ.)]. doi: 10.21518/2079-701X-2017-12-82-88/
29. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8. doi: 10.1016/ j.jacc.2007.03.025
30. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1:1504-14. PMID: 12871286
31. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al; for the APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708. doi: 10.1056/NEJMoa1105819
32. Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol. 2017;33:1027-35. doi: 10.1016/j.cjca.2017.06.001
33. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al; for the ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19. doi: 10.1056/NEJMoa1112277
34. Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30. doi: 10.1056/NEJMoa1709118
35. Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, et al. Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS TIMI 54. J Am Coll Cardiol. 2017;70:1368-75. doi: 10.1016/j.jacc.2017.07.768
36. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al; on behalf of the COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017. doi: 10.1016/S0140-6736(17)32458-3/
37. [The significance of COMPASS study results for clinical practice. Conclusion of the Board of Experts of November 22, 2017. Atherothrombosis. 2018;(1):19-25 (In Russ.)].
1 ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово, Россия;
2 ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России, Кемерово, Россия
________________________________________________
O.L. Barbarash 1,2, V.V. Kashtalap 1,2
1 Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia;
2 Kemerovo State Medical University, Kemerovo, Russia